Pharmaceutical Business News

Merck’s Keytruda helps lung cancer patients live longer in trial

Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market. Merck is already considered the frontrunner in the space and Keytruda is expected to earn peak sales of over $10 billion in 2023, according to Credit Suisse. Keytruda is already approved in the U.S. to treat patients with
cancer

New Biotechnology Partnership Formed to Develop Liver Cancer Chemotherapeutic

Q BioMed, Inc., a New York City-based biomedical acceleration and development company has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer. The technology will utilize “uttroside B” and the compound’s derivatives as a chemotherapeutic agent against hepatocellular carcinoma. The preclinical efficacy of uttroside B, a potent saponin, against liver cancer